Chongqing Zhifei Biological Products Co.,Ltd.
Chongqing Zhifei Biological Products Co., Ltd. (Zhifei) started to engage in the industry of biological products in 2002. Now, it has a registered capital of RMB 1.6 billion and over 2,400 employees as well as RMB 6.2 billion in assets. In September 2010, Zhifei was listed on the Shenzhen Stock Exchange (stock code: 300122), becoming the first privately-run vaccine enterprise listed on ChiNext. Zhifei has five wholly-owned subsidiaries and a joint-stock subsidiary, of which Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. are new high-tech enterprises.
As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use, which is one of seven strategic emerging industries of China and has a broad development prospect. Now, its independent products on sale include Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine,(MenAC-Hib) Haemophilus Influenzae Type b Conjugate Vaccine(Hib), Group ACYW135 Meningococcal Polysaccharide Vaccine (Menwayc®), Mycobacterium Vaccae for Injection (Vaccae®) and Meningococcal Group A and C Conjugate Vaccine (MeningACon®). Meantime, Zhifei is the sole distributor of the vaccines of Merck Sharp & Dohme(MSD) such as HPV4(Gradasil),HPV9(Gradasil 9),5-valent rotavirus vaccine(Rotateq),23-valent Pneumonia vaccine(Pneumovax 23),Hepatitis A vaccine(Vaqta).
Through the dual-wheel driving pattern characterized by “R&D + Marketing”, Zhifei has formed a good cycle mechanism which succeeds in realizing the mutual facilitation and mutual transformation between R&D and marketing, accelerating the commercialization process of vaccine products and gradually forming its core competitiveness which is uniquely characteristic and leads the market.
Zhifei has built up an R&D team composed of experts with outstanding quality and always attaches importance to the introduction and development of technology. Zhifei has successively participated in over 20 major projects such as 863 High-Tech Program entitled "Modern Medical Technology", “Major New Drugs Innovation and Development” under Ministry of Science and Technology and other state's major projects. Zhifei has two R&D bases and 22 ongoing projects including those that are under BLA reviews, clinical trials, and preclinical studies, including human vaccines for prevention of meningitis, tuberculosis, pneumonia, flu, rabies and gastroenteritis. At present, Zhifei has obtained 6 GMP certificates, 15 patents for invention and 12 patents pending. In 2014, Zhifei successfully launched an independently developed and patented product MenAC-Hib. Meanwhile, to further extend its business scope and scale, Zhifei began to make strategic arrangement, entering into the industry of therapeutic biological products.
In addition, Zhifei has constructed its in-depth service network with comprehensive coverage, which supplies sustainable, rapid and all-sided first-rate service for more than 30,000 points of vaccination (POVs) (township POVs and community outpatient clinics) of over 2,600 districts or counties in more than 300 cities of 31 provinces, autonomous regions and municipalities directly under the Central Government across the country. At the same time, by self-building its cold chain system conforming to national GSP requirements, Zhifei has realized a seamless cold chain with regard to the storage and transportation of vaccines. Through the real time temperature monitoring system, vaccine products can be transported to various county-level CDCs safely and soundly by refrigerated vehicles that can realize long-distance automation monitoring and alarm.
Since its establishment, Zhifei has always adhered to the business philosophy of "Social benefits go before corporate profits" and its core value featuring "six firsts and six seconds". Aiming at enhancing people’s awareness of disease prevention as its mission, Zhifei has successively rolled out over ten vaccines against various diseases on the market, promoting the development of public health and creating good social benefits. Zhifei regards social public welfare undertaking as the important channel for repaying society and shouldering social responsibility and has made positive contribution to the development of grass-roots healthcare and educational causes. In February 2018, together with China Population Welfare Foundation and China Preventive Medicine Association, Zhifei launched the establishment of the Escort Disease Control Fund under China Population Welfare Foundation and donated RMB 10 million for facilitating the development of the cause of disease prevention and control. In December 2017, Zhifei donated over RMB 20 million for the development of the health care of Chinese females' cervixes. At the same time, Zhifei has successively raised or donated money to China Red Cross Foundation, Chongqing Charity Association, rural schools, university libraries and so forth for improving the condition of primary health care institutions, perfecting school facilities and subsidizing rural poverty-stricken schools and needy children influenced by AIDS to receive education and treatment. In recent years, Zhifei has accumulatively donated over RMB 100 million.
On the strength of its unremitting development for over a decade, Zhifei has been well recognized by all walks of life and won honorary titles such as one of Top 100 CPC Party Organizations of non-public enterprises that are strong both in Party building and development, Chongqing Role Model in Ethical and Cultural Progress, National Level Enterprises of Observing Contract & Valuing Credit, National Pilot Enterprise in Business Integrity, Innovative Enterprise in Chongqing and Top 100 Manufacturing Enterprises in Chongqing.
1.6Registered capital（RMB Billion）